ERBB2 and breast carcinoma: Patients carrying the T allele had higher frequency of ER-positive or HER2-negative tumors when compared with wild type carriers in the present study and the lack of expression of hormonal receptors or the triple-negative molecular subtype of breast cancer were indeed significant predictors of poor DFS.